The aim of this study was to confirm the dose-dependent skin moisturizing effects of dried pomegranate concentrate powder (PCP) and pomegranate concentrate solution (PCS) in ICR mice. Materials and methods: To observe the in vivo skin moisturizing effects and possible underlying mechanisms of PCP and PCS, oral PCP (100, 200, and 400 mg/kg) and PCS (1, 2, and 4 mL/kg) were administered to normal ICR mice. Changes in body weight, skin water content, and skin type I collagen and hyaluronan contents were measured. Additionally, the mRNA expression levels of hyaluronan synthase (Has) 1, 2, and 3, and collagen type I alpha (COL1A) 1 and 2 were determined in the dorsal skin of mice by real-time reverse transcription polymerase chain reaction (RT-PCR). Results: Significant and dose-dependent increases in dorsal skin water content and type I collagen and hyaluronan contents were seen in PCP and PCS-treated mice. Moreover, the mRNA levels of Has 1, 2, and 3, involved in hyaluronan synthesis, and of COL1A1 and COL1A2, involved in collagen synthesis, were significantly and dose-dependently upregulated in PCS-and PCP-treated mice. Conclusions: In this study, PCP and PCS led to favorable skin moisturizing effects as indicated by increased skin water content and the upregulation of hyaluronan and collagen synthesis enzymes in mice treated with PCS (4 mL/kg) and PCP (200 mg/kg). 
Introduction
Skin aging results in clinical signs including irregular dryness, dark or light pigmentation, sallowness, deep furrows or severe atrophy, dehydrogenation, telangiectasia, premalignant lesions, laxity, and a leathery appearance 1) . Various complex cellular and extracellular components are involved in the skin-aging phenomenon; several studies highlight the involvement of reactive oxygen species (ROS) 2) , the degradation of the extracellular matrix (ECM) 3) and melanin pigmentation 4) , and a decrease in moisture of the skin keratin layers 5, 6) . Functional anti-aging skin protective agents have focused on antioxidant, anti-wrinkle, whitening, and skin moisturizing effects as their underlying mechanisms of action. Various antioxidants that reduce ROS and scavenge free radicals, such as ascorbic acid, α-tocopherol, carotenoid, flavonoid, butylated hydroxy toluene, butylated hydroxy anisole, and propylene glycol, have been used as ingredients in anti-aging protective agents [7] [8] [9] . The antioxidant efficacy of such agents has been tested via free radical scavenging or effects on the activity of antioxidant enzymes that contribute to enzymatic defense mechanisms, including superoxide dismutase (SOD) 10) . Their anti-wrinkle and skin regeneration effects have been assessed via the activities of various dermal enzymes involved in the formation of skin wrinkles and the degradation of the ECM, including hyaluronidase, elastase, collagenase, and matrix metalloproteinase (MMP-1) 3, 11) . Moreover, the whitening effects of such agents have been measured using skin melanin content as well as tyrosinase activity, an enzyme involved in melanin formation 4, 9, 12, 13) , while their skin moisturizing effects have been detected by measuring skin water content in animal and human pilot studies 9, 14, 15) .
Pomegranate is a rich source of crude fiber, pectin, sugars, and several tannins 16) . In addition, pomegranate seed oil and juice contain flavonoid and anthocyanidin species, which exert an antioxidant activity that is three-fold more potent than that of red wine or green tea extract 17, 18) . Furthermore, the chemopreventive and adjuvant therapeutic applications of pomegranate to human breast cancer have been recently 19) . Owing to these significant biological activities, the popularity of pomegranate juice has risen worldwide. We have previously reported the favorable in vitro and in vivo skin protective effects of a pomegranate concentrate solution (PCS), including its possible skin moisturizing effects in vitro 20, 21) . However, detailed studies investigating the underlying mechanisms of action and demonstrating the skin-moisturizing effects of PCS and pomegranate concentrate powder (PCP) in vivo are warranted.
The objective of the this study was to confirm the dose-dependent skin moisturizing effects of PCP and PCS in normal ICR mice, as well as to determine their possible underlying mechanisms of action, focusing on hyaluronan and type I collagen synthesis. To do so, changes in body weight, and skin water, type I collagen, and hyaluronan contents, as well as mRNA expression of enzymes involved in hyaluronan synthesis, including hyaluronan synthase (Has) 1, 2, and 3, and collagen synthesis, including collagen type I alpha (COL1A) 1 and 2, were measured in the dorsal skin of mice.
Materials and Methods

Animals
Healthy 6-week old male SPF/VAF outbred CrljOri:CD1 (ICR) mice (OrientBio, Seungnam, Korea) were used after acclimatization for 7 days. Five mice were allocated per polycarbonate cage in a temperature (20-25ºC) and humidity (45-55%) controlled room with a 12 hour light-dark cycle. Mice had ad libitum access to chow (Samyang, Seoul, Korea) and water. All laboratory animals were treated according to the national regulations of the (182) usage and welfare of laboratory animals, and approved by the Institutional Animal Care and Use Committee in Daegu Haany University (Gyeongsan, Gyeongbuk, Korea) prior to animal experiment. (1,000 mg/60 kg) × 12 = 200 mg/kg), and dosages of 400 and 100 mg/kg were selected as the highest and lowest dosages, respectively, using a ratio of 2. Similarly, a PCS dosage of 2 mL/kg was selected based on previous clinical dosages used in humans (mouse dosage ~12-fold the human dosage; (10 mL/60 kg) × 12 = 2 ml/kg), and dosages of 4 and 1 mL/kg were selected as the highest and lowest dosages, respectively, using a ratio of 2. PCP was dissolved in distilled water to obtain concentrations of 40, 20, and 10 mg/mL, and a volume of 10 mL/kg of body weight was orally administered, resulting in administration of 400, 200, and 100 mg/kg of body weight, respectively. PCS was diluted in distilled water in 2:3, 1:4, and 1:9 ratios (v/v) and a volume of 10 mL/kg was orally administered, resulting in administration of 4, 2, and 1 mg/kg of body weight, respectively. The different dosages of PCP and PCS were administered in six different groups of mice once per day for 56 days, and equal volumes of vehicle (distilled water) were orally administered in a separate group of intact control mice.
Treatments
Body weight
Changes in body weight were measured once a week, from one day prior to the beginning of treatment to sacrifice, including the second and the last (56 th ) treatment day, using an automatic electronic balance (Precisa Instrument, Dietikon, Switzland). Animals were overnight fasted prior to the first treatment day and termination to reduce differences in feeding. Body weight gain during the 8-week treatment period was calculated as follows: body weight gain (g) = (body weight at sacrifice) -(body weight on the first treatment day).
Skin water content
Twenty-four hours following the final treatment, 6 mm-diameter dorsal skin samples were collected from all mice. Skin water content (%) was measured using an automated moisture analyzer balance (Ohaus, Pine Brook, NJ, USA) as described in our previous report 9) .
Collagen type I content in skin tissue
Dorsal skin type I collagen content was measured according to a previously established method 10) . Briefly, dorsal skin tissue samples collected 24 h following the final treatment administration were homogenized and prepared using a bead beater (GeneResearch Biotechnology Corp., Taichung, Taiwan), an ultrasonic cell disruptor (Madell Technology Corp., Ontario, CA, USA) and radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, St. Louise, MO, USA). The supernatant was separated by centrifugation at 15,000 rpm at 4 °C, and the amount of pro-collagen in each sample was measured using a pro-collagen type I C peptide assay kit (Takara Bio, Tokyo, Japan) according to the manufacturer's instructions. Absorbance was measured at 450 nm (183) using a microplate reader (Tecan, Männedorf, Switzerland).
Hyaluronan content in skin tissue
Hyaluronan content of the prepared supernatant from dorsal skin tissue homogenate samples was measured according to a previously established method 22, 23) . Briefly, dorsal skin samples were defatted using acetone, dried, boiled in 50 mM Tris/HCl (pH 7.8) buffer for 20 min, and subjected to proteolytic digestion with 1% w/v actinase E (Sigma-Aldrich, St. Louise, MO, USA) for a week at 40 °C. Trichloroacetic acid (Sigma-Aldrich, St. Louise, MO, USA) was added to the samples at a final concentration of 10% w/v for deproteinization before centrifugation at 3,000 rpm at 4 °C for 20 min. The resulting supernatant was neutralized with 10 N NaOH. Hyaluronan levels were measured using the OnE hyaluronic acid enzyme-linked immunosorbent assay (ELISA) kit (Biotech Trading Partners, Encinitas, CA, USA) according to the manufacturer's instructions. Properly diluted samples and hyaluronan reference solutions were incubated in hyaluronic acid binding protein (HABP)-coated microwells. After washing to remove unbound molecules, HABP conjugated with horseradish peroxidase was added to the microwells to form complexes with hyaluronan. The samples were subsequently washed and tetramethylbenzidine, a chromogenic compound, and hydrogen peroxide were added, resulting in a colored reaction. Color intensity was measured in optical density units using a spectrophotometer (OPTIZEN POP, Mecasys, Daejeon, Korea) at 450 nm. Hyaluronan levels in the test and control samples were determined against a reference curve prepared from a reagent blank (0 ng/mL) as well as the hyaluronan reference solutions provided in the kit (50, 100, 200, 500, and 800 ng/mL).
Real-Time RT-PCR
Total RNA in the dorsal skin samples collected 24 h following the final treatment was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to a previously established method 23, 24) . RNA concentration and quality were determined using the CFX96 TM Real-Time System (Bio-Rad, Hercules, CA, USA). To remove contaminating DNA, samples were treated with recombinant DNase I (Ambion, Austin, TX, USA). RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Briefly, a cDNA strand was synthesized from the total RNA and the cDNA was amplified by PCR under the following conditions: 58 °C for 30 Table 1 .
STATISTICAL ANALYSIS
All values are expressed as the mean ± standard deviation (SD) of ten samples. The obtained data were analyzed by one-way analysis of variance (ANOVA), followed by the least-significant differences (LSD) multi-comparison test to determine significant differences. Statistical analyses were conducted using SPSS ver. 14.0 for Windows (SPSS Inc., Chicago, IL, USA). Differences were considered statistically significant at a value of P < 0.05.
Results
Body weight and body weight gain
No significant changes in body weight were observed in PCP-and PCS-treated mice compared with vehicle-treated control mice throughout the experimental period (Table 2, Fig 1) . As compared with control mice, the percent body weight gain of PCS-treated mice during the 56-day treatment period was 6.50%, 0.60%, and 1.81% in mice administered 4, 2, and 1 mL/kg of PCS, respectively, while that of PCP-treated mice was 1.81%, -0.15%, and 3.17% in mice administered 400, 200, and 100 mg/kg of PCP, respectively. 
Changes in skin water content
Significant increases in skin water content were observed in mice administered 4 and 2 mL/kg of PCS and 400, 200, and 100 mg/kg of PCP at the end of the treatment period compared with control mice. Further, mice administered 1 mL/kg of PCS showed a marked, albeit non-significant, increase in skin water content compared with control mice (Fig  2) . The percent skin water content changes in PCS-treated mice were 38.12%, 28.35%, and 12.08% in mice administered 4, 2, and 1 mL/kg of PCS, respectively, compared with control mice. Moreover, those of PCP-treated mice were 55.87%, 38.58%, and 27.86% in mice administered 400, 200, and 100 mg/kg of PCP, respectively, compared with control mice.
Changes in skin collagen type I content
At the end of the treatment period, significant increases in skin type I collagen content were observed in mice administered all doses of PCS (4, 2, and 1 mL/kg) and PCP (400, 200, and 100 mg/kg) compared with control mice (Fig 3) . The percent type 1 collagen content changes in PCS-treated mice were 53.54%, 36.44%, and 25.83% in mice administered 4, 2, and 1 mL/kg of PCS, respectively, while those of PCP-treated mice were 69.35%, 53.83%, and 44.11% in mice administered 400, 200, and 100 mg/kg of PCP, respectively, compared with control mice.
Changes in skin hyaluronan content
Skin hyaluronan content was significantly increased in all groups treated with PCS (4, 2, and 1 mL/kg) ( 186) and PCP (400, 200, and 100 mg/kg) compared with control mice at the end of the treatment period (Fig  4) . The percent hyaluronan content changes in PCS-treated mice were 44.79%, 32.94%, and 25.24% in mice administered 4, 2, and 1 mL/kg of PCS, respectively. Moreover, those of PCP-treated mice were 55.54%, 44.22%, and 43.98% in mice administered 400, 200, and 100 mg/kg of PCP, respectively.
Effects on skin hyaluronan synthase genes
Significant increases in skin Has 1, Has 2, and Has 3 mRNA expression were observed in mice treated with all doses of PCS (4, 2, and 1 mL/kg) and PCP (400, 200, and 100 mg/kg) compared with control mice at the end of the treatment period ( Table 3 ). The percent increases in skin Has 1 mRNA expression levels in PCS-treated mice were 54.52%, 43.22%, and 34.09% in mice administered 4, 2, and 1 mL/kg of PCS, respectively, while those of PCP-treated mice were 65.03%, 55.11%, and 43.71% in mice administered 400, 200, and 100 mg/kg of PCP, respectively. Has 2 mRNA expression levels increased 45.40%, 31.40%, and 25.60% in PCS-treated mice at doses of 4, 2, and 1 mL/kg, respectively, and 56.10%, 46.50%, and 35.70% in PCP-treated mice at doses of 400, 200, and 100 mg/kg, respectively, compared with control mice. Lastly, the skin mRNA levels of Has 3 increased 58.65%, 43.16%, and 30.08% in mice treated with 4, 2, and 1 mL/kg of PCS, respectively, and 79.98%, 59.46%, and 45.88% in mice treated with 400, 200, and 100 mg/kg of PCP, respectively, compared with control mice.
Effects on skin collagen type I synthetic genes
Significant increases in skin COL1A1 and COL1A2 mRNA expression were observed in mice treated with all doses of PCS (4, 2, and 1 mL/kg) and PCP (400, 200, and 100 mg/kg) compared with control mice at the end of the treatment administration period (Table 3 ). The percent increase in skin COL1A1 mRNA expression levels in PCS-treated mice was 52.30%, 43.50%, and 31.83% in mice administered 4, 2, and 1 mL/kg of PCS, respectively, while that of PCP-treated mice was 75.33%, 57.83%, and 46.06% in mice administered 400, 200, and 100 mg/kg of PCP, respectively, compared with control mice. Skin COL1A2 mRNA expression levels increased 53.84%, 44.32%, and 33.67% in PCS-treated mice at doses of 4, 2, and 1 mL/kg, respectively, and 75.33%, 55.99%, and 46.06% in PCP-treated mice at doses of 400, 200, and 100 mg/kg, respectively, compared with control mice.
Discussion
Functional skin protective agents contain specific ingredients that have potent pharmacological actions, which can be divided into anti-aging, whitening, anti-wrinkle, moisturizing, and skin protective effects 8) . Specifically, their anti-aging effects have been demonstrated by testing their antioxidant and free radical scavenging actions as well as their effects on the activity of antioxidant enzymes that contribute to enzymatic defense mechanisms 10) . The skin regeneration and anti-wrinkle effects of these protective agents have been demonstrated by assessing the activities of various dermal enzymes involved in the formation of skin wrinkles 3, 11) . In addition, their whitening effects have been measured based on skin melanin content and the activity of tyrosinase, an enzyme involved in melanin formation 4, 12, 13) , while their skin-moisturizing effects have been detected by measuring skin water content in animals and in human pilot studies 5, 6, 9, 14, 15) . Therefore, various skin protective products have been developed for anti-aging, whitening, anti-wrinkle, moisturizing, and skin protective purposes [4] [5] [6] 9, 14, 15) . However, currently available anti-aging skin protective agents have a number of limitations, including high costs and pharmacological and side effects that are not fully understood 25) . Due to these factors, various efforts have been made to find an affordable and functional skin-protective ingredient with few side effects, focusing on natural antioxidants 2, 8, 9, 21, 26) . In this study, significant and dose-dependent increases in skin water, type I collagen, and hyaluronan contents were demonstrated in mice treated with various doses of PCP and PCS, compared with vehicle-treated control mice. Moreover, the mRNA expression of Has 1, Has 2, and Has 3, involved in hyaluronan synthesis and of COL1A1 and COL1A2, involved in collagen synthesis, were significantly and dose-dependently increased in dorsal skin samples of PCP and PCS-treated mice. Additionally, treatment with PCP at a dose of 200 mg/kg of body weight showed similar in vivo skin moisturizing effects to treatment with PCS at a dose of 4 mL/kg of body weight. Thus, treatment with both PCP and PCS resulted in favorable skin moisturizing effects in normal mice through the upregulation of mRNA expression of genes involved in hyaluronan and collagen synthesis.
Keratin layers in the human skin maintain skin hydration; they are composed of 10-20% water. However, decreases in keratin layer water content accelerates the aging process, wrinkle formation, and itching 6) . To maintain healthy elastic skin, keratin layers must retain adequate moisture, even under dry conditions 27) . Skin moisturizing effects have previously been measured in animal and human studies by assessing the skin's water content 9, 14, 15) . In this study, significant and dose-dependent increases in dorsal skin water content were demonstrated in all PCSand PCP-treated mice compared with vehicle-treated control mice. Thus, both PCS and PCP exert favorable skin-moisturizing effects, which could be used in a functional skin protective product.
Type I collagen is the major structural protein in the skin. Collagen destruction is the main underlying mechanism thought to contribute to the appearance of aged skin due to chronic sun exposure 28) . Skin wrinkling is a complex but inevitable process that involves the age-dependent decline of skin cell function, causing harmful proteolytic degradation of the ECM 3) . Several scientific studies investigating skin wrinkling have highlighted that ECM degradation is significantly associated with increased dermal activity of enzymes including hyaluronidase, collagenase, elastase, and MMP-1 to form wrinkles 3, 11) . Ingredients (188) that promote type I collagen synthesis or inhibit the activity of enzymes involved in ECM degradation in aged skin have the potential for use in anti-wrinkle and moisturizing skin-care products 1, 10) . In our previous in vitro experiments 20) , fibroblast (HDF-N cell) treatment with PCS influenced type I collagen synthesis, and favorably inhibited hyaluronidase and MMP-1 activities. In this study, PCP and PCS treatment resulted in dose-dependent increases in skin collagen type I content, with upregulation of the collagen synthetic genes COL1A1 and COL1A2; comparable results were obtained with a PCS dose of 4 mL/kg and a PCP dose of 200 mg/kg. Both the COL1A1 and COL1A2 genes are involved in type I collagen synthesis by producing the pro-alpha1(I) and pro-alpha2(I) chains that form a type I procollagen molecule 29) . Thus, PCS and PCP may exert their favorable skin moisturizing actions, in part, by increasing collagen synthesis.
Hyaluronan is a major ECM component of the skin that plays important roles in skin physiology, including maintaining water homeostasis 20, 23, 30) Hyaluronan is synthesized by three proteins, Has 1, Has 2, and Has 3 23, 31, 32) . Similar to our previous in vitro study 20) , in which PCS treatment favorably increased hyaluronan synthesis in HaCaT cells, significant and dose-dependent increases in skin hyaluronan content as well as Has 1, Has 2, and Has 3 gene upregulation were demonstrated in all PCSand PCP-treated mice. These results indicate that the skin-moisturizing effects of PCS and PCP are exerted, in part, by an increase in hyaluronan synthesis.
This study demonstrates the beneficial skin-moisturizing effects of PCP and PCS in normal mice, and highlights potential underlying mechanisms, including upregulation of mRNA expression of genes involved in hyaluronan and collagen synthesis. Similar results were obtained in mice administered PCP at a dose of 200 mg/kg and in mice administered PCS at a dose of 4 mL/kg. Thus, PCP and PCS exert promising potent anti-aging effects that may be beneficial in functional skin protective agents.
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